PAVmed targets early 2027 Veris 510(k) submission while pursuing PortIO 510(k) pathway (NASDAQ:PAVM)
· seekingalpha.com
PAVmed (PAVM) Q2 2026 earnings call recap: Lucid Medicare coverage, Veris implantable 510(k) timing, PortIO/Octeris FDA steps & cash.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...